December 10, 2019
1 min read

Enrollment in ocular graft-versus-host disease trial halfway complete

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Ocugen has completed 50% of enrollment for a phase 3 trial of OCU300 for the treatment of ocular redness and discomfort in patients with ocular graft-versus-host disease, according to a press release.

The double-masked, placebo-controlled 84-day trial will include 60 patients randomly assigned 2:1 to receive OCU300 (brimonidine 0.18% nanoemulsion) or placebo.

“The achievement of 50% enrollment is a key milestone towards the completion of this important phase 3 trial. [Ocular graft-versus-host disease] is a severe ocular autoimmune disease that occurs in up to 60% of allogeneic bone marrow transplant patients,” Daniel Jorgensen, MD, MPH, MBA, Ocugen chief medical officer, said in the release. “There is no approved therapy for this debilitating condition, and it is our belief that OCU300 will provide needed relief for patients suffering from this disease.”

Topline results of the trial are expected in the second half of 2020.